TMEM230 may be a novel candidate gene target to repress both tumor cell properties and tumor driven angiogenesis and consequently in the improvement of patient overall survival, not just for patients with high-grade glioblastoma and low-grade gliomas but also other types of abnormally vascularized tumors. This evidence concerns the gene TMEM230 and glioma.